Latest Close
$2.09
Stock Hub
SERA
Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
-$1.21 (-36.82%)
Market Cap
$82,252,136.00
Sector
Healthcare
Industry
Medical Devices
Recommendation
none
52W Range
$1.56 to $3.95
Target Mean Price
$5.50
Beta
0.98
Trailing P/E
Not available
Forward P/E
-3.90
Price / Book
1.38
Company Overview
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.